Company / Cash & Equivalents
Inogen Inc Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$103.7M
FY2025
5-year range
$103.7M / $235.5M
FY2021-FY2025
Trend
-17.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $125M to $104M over the past 2 years.
Based on SEC 10-K filings.
$104M in FY2025 with a 5-year CAGR of -13.3%.
Declined from $125M to $104M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.8%
- 5-Year CAGR
- -13.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -13.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 17.3% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $103.7M | -17.3% |
| FY2024 | $125.5M | +0.0% |
| FY2023 | $125.5M | -32.9% |
| FY2022 | $187.0M | -20.6% |
| FY2021 | $235.5M | +11.1% |
| FY2020 | $212.0M | +7.0% |
| FY2019 | $198.0M | +0.7% |
| FY2018 | $196.6M | +111.8% |
| FY2017 | $92.9M | +63.4% |
| FY2016 | $56.8M | +320.4% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026